BLD-2660

Phase 2Small molecule

BBlade Therapeutics

BLD-2660 is one of 64 small molecule programs targeting Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FibrosisActive, not recruiting

COVID-19Active, not recruiting

FibrosisPhase 1

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bnt162b2

BioNTech

Preclinical

29 2

BLD-2660

BBlade Therapeutics

Phase 2

1 3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 5

Aprotinin

Bayer

Preclinical

1 6

Antithrombin-III

Octapharma

Preclinical

1 7

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 8

MRNA COVID-19 Vaccine

Novartis

Preclinical

4 9

Tpa

UUniversity of Florida

Preclinical

1 10

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

Completed·BBlade Therapeutics·Phase 2·NCT04334460·120 enrolled

Oral1 trial

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

Withdrawn·BBlade Therapeutics·Phase 2·NCT04244825

MPA1 trial

Healthy Volunteer Study Comparing Tablet and Capsule Formulations

Withdrawn·BBlade Therapeutics·Phase 1·NCT04001998

Fibrosis1 trial

First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis

Completed·BBlade Therapeutics·Phase 1·NCT03559166·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BLD-2660. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BLD-2660 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BLD-2660. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Blade Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBlade Therapeutics

BLD-2660

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

Oral1 trial

MPA1 trial

Fibrosis1 trial

References

Drug Info

Quick Facts

Related News